AI assistant
Sending…
HARROW, INC. — Director's Dealing 2016
Dec 21, 2016
31774_dirs_2016-12-21_6dbf997d-7b64-4000-80de-b0ea382fd55f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Imprimis Pharmaceuticals, Inc. (IMMY)
CIK: 0001360214
Period of Report: 2016-12-19
Reporting Person: LINDSTROM RICHARD L MD (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-12-19 | Common Stock | P | 100000 | $1.79 | Acquired | 100000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-12-19 | Purchase Warrant | $1.79 | P | 100000 | Acquired | 2019-12-23 | Common Stock (100000) | Direct |
Footnotes
F1: On December 19, 2016 Dr. Lindstrom entered into a definitive agreement to acquire 100,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.
F2: The value of the Purchase Warrant included in each Unit is $0.125.
More from HARROW, INC.
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 24
Regulatory Filings
2026
Mar 24
Director's Dealing
2026
Mar 3
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 2
Director's Dealing
2026
Feb 2
Regulatory Filings
2026
Feb 2
Director's Dealing
2026
Jan 8